FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, anti-cancer therapy, and concerns a method of treating lymphoma specified in diffuse large B-cell lymphoma, marginal zone lymphoma and nodular sclerosis Hodgkin lymphoma by means of an organic derivative of arsenic, such as darinaparsin (S-dimethylarsinoglutathione, SGLU-1):
or its pharmaceutically acceptable salt. The administration is performed once a day for five days every four weeks in a dose of 200-420 mg/m2, in particular intravenously. The invention also concerns using the above compound or its pharmaceutically acceptable salt for preparing the respective drug and pharmaceutical compositions.
EFFECT: group of inventions provides the effective treatment of the above group of diseases with similar or higher activity or lower toxicity as compared to arsenic oxide.
8 cl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| N1-(4-(5-(CYCLOPROPYLMETHYL)-1-METHYL-1H-PYRAZOLE-4-YL)PYRIDINE-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF CK1 AND/OR IRAK1 FOR THE TREATMENT OF CANCER | 2018 |
|
RU2761457C2 |
| CYANOTHIENOTRIAZOLODIAZEPINES AND METHODS FOR THEIR USE | 2016 |
|
RU2750164C2 |
| BENZIMIDAZOLES USED AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2415853C2 |
| BENZO[b]THIOPHENE STING AGONISTS FOR TREATMENT OF CANCER | 2018 |
|
RU2771811C2 |
| BIVALENT BROMODOMAIN INHIBITORS AND ROUTES OF USE THEREOF | 2016 |
|
RU2742035C2 |
| COMBINATION THERAPY USING CC CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE CHECKPOINT INHIBITORS | 2019 |
|
RU2810717C2 |
| HETEROCYCLIC COMPOUNDS AND USES THEREOF | 2014 |
|
RU2680100C9 |
| METHOD FOR ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY STRENGTHENING | 2011 |
|
RU2627660C2 |
| COMBINED PRODUCTS CONTAINING TYROSINE KINASE INHIBITORS AND THEIR USE | 2013 |
|
RU2660354C2 |
| BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR TREATING CANCER | 2015 |
|
RU2741914C2 |
